Eric Cucchi, Asem Ali, Yurima Guilarte-Walker, Bruce Barton, Samir Malkani, John Mordes
{"title":"Accuracy of a Continuous Glucose Monitor in the Intensive Care Unit.","authors":"Eric Cucchi, Asem Ali, Yurima Guilarte-Walker, Bruce Barton, Samir Malkani, John Mordes","doi":"10.1177/15209156261423933","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Continuous glucose monitoring (CGM) devices are routinely used in the outpatient management of diabetes. They are not yet approved for use in intensive care units (ICUs). The main objective of this study was to determine the accuracy of CGM glucose determinations made in an ICU by comparing them with standard glucose measurements obtained during routine care. Secondary objectives were to determine the frequency of device malfunctions or adverse events and to assess acceptance of CGM use by caregivers.</p><p><strong>Methods: </strong>Dexcom™ G7 CGM sensors were placed on non-randomized, consented ICU patients with known hyperglycemia. CGM glucose concentrations were recorded in a Dexcom Clarity™ database and compared with near-simultaneous (±5 min) measurements obtained by laboratory or point-of-care measurements recorded in an electronic medical record. Determinations of accuracy were made using a Clarke Error Grid plot and by calculating mean absolute relative difference (MARD). Device failure and adverse event data were recorded in the electronic record. Caregiver acceptance was assessed by interview.</p><p><strong>Results: </strong>During a 9-month period, 16 subjects were enrolled after obtaining informed consent. The median duration of CGM use on subjects was 5.5 (range 1-20) days. A total of 941 near-simultaneous CGM and routine care data were collected. Clarke Error Grid comparison of CGM and routine care data showed 99.7% of readings in regions A or B and 0.3% in other regions. The MARD of all readings was 12.25%. There were no adverse events attributable to the CGM recorded. Qualitative analysis of nursing responses revealed no concerns regarding the addition of CGM to the routine workflow.</p><p><strong>Conclusion: </strong>CGM glucose readings in the ICU may be reliable to use in certain critically ill patient populations. CGM may not be reliable in patients requiring high-dose vasopressors. The use of CGM to enhance patient care in ICUs merits additional research.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"916-923"},"PeriodicalIF":7.4000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15209156261423933","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Continuous glucose monitoring (CGM) devices are routinely used in the outpatient management of diabetes. They are not yet approved for use in intensive care units (ICUs). The main objective of this study was to determine the accuracy of CGM glucose determinations made in an ICU by comparing them with standard glucose measurements obtained during routine care. Secondary objectives were to determine the frequency of device malfunctions or adverse events and to assess acceptance of CGM use by caregivers.
Methods: Dexcom™ G7 CGM sensors were placed on non-randomized, consented ICU patients with known hyperglycemia. CGM glucose concentrations were recorded in a Dexcom Clarity™ database and compared with near-simultaneous (±5 min) measurements obtained by laboratory or point-of-care measurements recorded in an electronic medical record. Determinations of accuracy were made using a Clarke Error Grid plot and by calculating mean absolute relative difference (MARD). Device failure and adverse event data were recorded in the electronic record. Caregiver acceptance was assessed by interview.
Results: During a 9-month period, 16 subjects were enrolled after obtaining informed consent. The median duration of CGM use on subjects was 5.5 (range 1-20) days. A total of 941 near-simultaneous CGM and routine care data were collected. Clarke Error Grid comparison of CGM and routine care data showed 99.7% of readings in regions A or B and 0.3% in other regions. The MARD of all readings was 12.25%. There were no adverse events attributable to the CGM recorded. Qualitative analysis of nursing responses revealed no concerns regarding the addition of CGM to the routine workflow.
Conclusion: CGM glucose readings in the ICU may be reliable to use in certain critically ill patient populations. CGM may not be reliable in patients requiring high-dose vasopressors. The use of CGM to enhance patient care in ICUs merits additional research.
期刊介绍:
Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.